Neuren Pharmaceuticals Limited (NURPF) Research

Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes. In addition to its drug pipeline, Neuren provides development-related services and possesses investments in loan-backed shares. The firm was established in 2001 and operates from its base in Camberwell, Australia.

Market snapshot

Symbol
NURPF
Price
$8.69
Day change
+2.48%
Market cap
$1.6B
P/E ratio
53.01x
52-week range
7.7-14.7965
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Anebulo Pharmaceuticals, Inc. (ANEB)
  • Assembly Biosciences, Inc. (ASMB)
  • Aerovate Therapeutics, Inc. (AVTE)
  • Cerevel Therapeutics Holdings, Inc. (CERE)
  • Compass Therapeutics, Inc. (CMPX)
  • Crinetics Pharmaceuticals, Inc. (CRNX)
  • Champions Oncology, Inc. (CSBR)
  • Cyteir Therapeutics, Inc. (CYT)

Open Neuren Pharmaceuticals Limited (NURPF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.